Skip to main content
Grand Pharmaceutical Group Limited logo

Grand Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 512 ISIN · BMG210A71016 LEI · 8945001XW4FS15S8Z778 HKEX Manufacturing
Open in API
Filings indexed 1,169 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country BM Bermuda
Listing HKEX 512

About Grand Pharmaceutical Group Limited

http://www.grandpharma.cn

Grand Pharmaceutical Group Limited is an international, technology-driven pharmaceutical enterprise specializing in the research, development, manufacture, and sale of innovative healthcare solutions. The company's strategic focus encompasses three primary areas: pharmaceutical technology, nuclear medicine for anti-tumor diagnosis and treatment, and cerebro-cardiovascular precision intervention. Key product lines include anti-tumor and cardiovascular emergency pharmaceutical products, as well as intervention medical devices. The organization maintains a strong commitment to R&D, actively developing next-generation therapies, such as mRNA drugs designed to combat tumors and infections. Additionally, the company provides a range of bio-health products, including amino acid and taurine series.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings
2026-05-04 English
Proxy Form for the annual general meeting to be held on Friday, 5 June 2026 or any adjournment thereof
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a proxy form for the annual general meeting, allowing shareholders to appoint proxies and vote on resolutions. This form is part of the materials sent to shareholders to solicit proxies and provide meeting information. Therefore, it falls under Proxy Solicitation & Information Statement (PSI).
2026-04-29 English
PROPOSED ADOPTION OF NEW BYE-LAWS
Regulatory Filings Classification · 1% confidence The document is a formal announcement under Hong Kong Listing Rule 13.51(1) regarding proposed amendments to the company’s bye-laws and the forthcoming shareholder vote at the AGM. It does not include the detailed bye-laws or circular itself, nor is it a full governance report or proxy solicitation package. Therefore it is best classified as a general regulatory announcement (RNS).
2026-04-29 English
(1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; (3)
Regulatory Filings
2026-04-29 English
Notice of Annual General Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a statutory Notice of Annual General Meeting setting out the meeting date, resolutions to be voted on (including financial statements adoption, dividend, director re–election, share mandates, bye-laws amendment), and proxy voting instructions. It is distributed to shareholders to request their votes on these items. This corresponds to our Proxy Solicitation & Information Statement category (code: PSI).
2026-04-29 English
2025 ESG report
Regulatory Filings
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.